Last reviewed · How we verify

NCT06060015

Effect of Subarachnoid Hyperbaric Bupivacaine in Obese Pregnant Patients Undergoing Cesarean Section

Status unknown Phase 4 Last updated 29 September 2023
What this trial tests

Phase 4 trial testing 5mg bupivacaine in Anesthesia in 106 participants. Status unknown.

Timeline
1 August 2023
Primary endpoint
31 October 2024
31 December 2024

Quick facts

Lead sponsorHospital Civil de Guadalajara
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment106
Start date1 August 2023
Primary completion31 October 2024
Estimated completion31 December 2024
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Civil de Guadalajara

Who can join

Adults 18 to 45, female only, with Anesthesia or Obstetric Anesthesia Problems. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluates the effect of hyperbaric subarachnoid bupivacaine at doses of 5 mg vs 10 mg on mean arterial pressure in obese pregnant patients undergoing cesarean section

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

Other Hospital Civil de Guadalajara trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06060015.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing